DnB Markets - Weifa ASA Continuing to deliver as planned

Report

DnB Markets

Patrik Ling

Continuing to deliver as planned

Weifa (WEIFA NO, Buy) - Continuing to deliver as planned
(13 pages)

13/07/2017 13 EN

Underlying

Weifa ASA

See profile

NO0010308240 Norway

Provider

DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

See profile

Analysts

Patrik Ling

Other Reports on these Companies

GlobalData Plc

Weifa ASA (WEIFA) - Oil & Gas - Deals and Alliances Profile

Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering products for pain relief; treatment of cough and colds; dermatology; Nutraceuticals; dietary supplements; and wound treatment among others. Its research and development activities focus on prescription drug products, OTC products and nutraceuticals. It offers products to consumers, customers and pro...

EUR 217.56

December 8, 2017 December 8, 2017 17 EN

DnB Markets

Voluntary offer made

Karo Pharma AB has made a voluntary offer to acquire all shares in Weifa. As DNB Markets has been engaged by Karo Pharma AB as a financial advisor in connection with the deal, we now have no recommendation (previously BUY) or target price (previously NOK35) on Weifa.

Free Trial

August 24, 2017 August 24, 2017 10 EN

Electrolux Professional (Hold, TP: SEK75.00) - Q4 looks set to be a repeat of Q3

We expect broadly similar market and divisional dynamics QOQ in Q4, but are less optimistic on growth in the US Food & Beverage segment (we now see the recovery materialising slightly later than initially envisaged). We forecast 6.0% growth YOY in group sales in Q4 and an adj. EBITA margin of 12.3%. We reiterate our HOLD, but have lowered our target price to SEK75 (79) based on our view of a delayed US Food & Beverage recovery as well as continued headwinds in the Middle East into 2025.

Free Trial

December 23, 2024 December 23, 2024 1 EN

Ebba Bjorklid

Ebba Bjorklid

Electrolux (Hold, TP: SEK92.00) - Uncertainty remains high

In Q4, we forecast similar demand and market dynamics to Q3, with consumer downtrading, elevated promotional activity, a negative mix, price pressure, and weak consumer demand weighing on sales and EBIT. We expect a sales decline of 1.6% YOY (organic growth of 2.6%) and an adj. EBIT margin of 3.2%. We reiterate our HOLD, but have cut our target price to SEK92 (94).

Free Trial

December 23, 2024 December 23, 2024 1 EN

Rune Majlund Dahl

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK1040.00) - Disappointing CagriSema data

In REDEFINE-1, CagriSema reached a 22.7% product estimand weight loss, shy of expectations. We expect a launch in 2026, but have lowered our estimate of its sales potential. In our view, the flexible protocol affected efficacy, prompting Novo Nordisk to initiate a new phase III trial in 2025. We reiterate our BUY, but have cut our target price to DKK1,040 (1,150).

Free Trial

December 20, 2024 December 20, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Continuing to deliver as planned

Weifa ASA (WEIFA) - Oil & Gas - Deals and Alliances Profile

Voluntary offer made

Electrolux Professional (Hold, TP: SEK75.00) - Q4 looks set to be a repeat of Q3

Electrolux (Hold, TP: SEK92.00) - Uncertainty remains high

Novo Nordisk (Buy, TP: DKK1040.00) - Disappointing CagriSema data

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe